The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
Market view
aflibercept-jbvf
3 marketed package NDCs · 3 active manufacturers
What changed in the last 90 days
Every detected change for aflibercept-jbvf, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
Same drug class
Other molecules FDA puts in Vascular Endothelial Growth Factor Inhibitor, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
- aflibercept-ayyh· 1 maker
- aflibercept-mrbb· 1 maker
- bevacizumab-awwb· 1 maker
- bevacizumab-nwgd· 1 maker
- bevacizumab-vikg· 1 maker
- ranibizumab-leyk· 1 maker
- ziv-aflibercept· 1 maker
- bevacizumab-adcd· 2 makers
- bevacizumab-bvzr· 2 makers
- bevacizumab-maly· 2 makers
- ranibizumab-eqrn· 2 makers
- ranibizumab-nuna· 2 makers
Common questions
- Is Aflibercept-jbvf in shortage right now?
- No. FDA does not currently list Aflibercept-jbvf in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Aflibercept-jbvf?
- 3 companies have marketed Aflibercept-jbvf in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.